Zacks Research Issues Positive Estimate for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Analysts at Zacks Research upped their Q2 2025 earnings estimates for Halozyme Therapeutics in a research report issued on Tuesday, March 11th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of $1.08 per share for the quarter, up from their prior estimate of $1.06. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q3 2025 earnings at $1.31 EPS, Q4 2025 earnings at $1.58 EPS, FY2025 earnings at $4.86 EPS, Q1 2026 earnings at $1.28 EPS, Q2 2026 earnings at $1.41 EPS, Q3 2026 earnings at $1.57 EPS, Q4 2026 earnings at $1.71 EPS and FY2026 earnings at $5.96 EPS.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%.

A number of other brokerages have also issued reports on HALO. Wells Fargo & Company dropped their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Finally, Benchmark reiterated a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Stock Up 2.0 %

Shares of NASDAQ:HALO opened at $62.27 on Friday. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The company has a fifty day simple moving average of $57.05 and a 200 day simple moving average of $54.70. The firm has a market cap of $7.67 billion, a PE ratio of 18.15, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics has a 12-month low of $37.73 and a 12-month high of $65.53.

Hedge Funds Weigh In On Halozyme Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Venturi Wealth Management LLC bought a new stake in Halozyme Therapeutics during the fourth quarter worth approximately $69,000. RPg Family Wealth Advisory LLC acquired a new position in Halozyme Therapeutics during the third quarter worth $1,886,000. Segall Bryant & Hamill LLC raised its stake in Halozyme Therapeutics by 16.3% during the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock worth $20,330,000 after acquiring an additional 49,856 shares in the last quarter. Retirement Systems of Alabama increased its stake in shares of Halozyme Therapeutics by 23.5% in the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock valued at $22,282,000 after buying an additional 74,173 shares in the last quarter. Finally, South Street Advisors LLC acquired a new stake in Halozyme Therapeutics in the third quarter worth about $9,812,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 1,697 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. This represents a 0.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 31,697 shares of company stock valued at $1,754,451 over the last 90 days. 2.40% of the stock is currently owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.